Merck Applauds Colombia for First PAHO/WHO Verification of Elimination of
Historic Milestone Reflects Successful Collaboration Among MECTIZAN^® Donation
Program and Partners
WHITEHOUSE STATION, N.J. -- July 29, 2013
Merck (NYSE: MRK), known as MSD outside the United States and Canada, applauds
the government of Colombia whose work with the MECTIZAN^® Donation Program and
The Carter Center-sponsored Onchocerciasis Elimination Program for the
Americas led to today’s Pan American Health Organization, the World Health
Organization’s Regional Office for the Americas (PAHO/WHO), verification of
Colombia as the first country in the world to eliminate the transmission of
river blindness (onchocerciasis), using MECTIZAN (ivermectin). Onchocerciasis
is one of the leading causes of preventable blindness worldwide.
“We are humbled by the great work of the MECTIZAN Donation Program and its
partners in protecting future generations of Colombians from a disease that
carries devastating implications for people, families, healthcare systems and
local economies,” said Kenneth C. Frazier, chairman and chief executive
officer, Merck. “It is tremendously rewarding to see the alliance of partners
achieve the long-held goal of making river blindness a disease of the past in
For more information, please view the news releases from:
*Colombia Ministry of Health and Social Protection (Spanish)
*MECTIZAN Donation Program
*Carter Center-sponsored Onchocerciasis Elimination Program for the
About the MECTIZAN Donation Program
In October 1987, Merck announced it would donate the medication MECTIZAN to
all who need it for as long as necessary until onchocerciasis is eliminated as
a public health problem. The MECTIZAN Donation Program reaches more than 100
million people annually. www.mectizan.org.
In Latin America, since 1989, more than 10 million treatments of donated
MECTIZAN have been delivered by community health workers and non-governmental
Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck patents
and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2012
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
Lainie Keller, 908-423-4187
Press spacebar to pause and continue. Press esc to stop.